Corcept Therapeutics

Corcept Therapeutics

Quarterly Financials

Values in thousands2026-03-312025-12-312025-09-302025-06-30
Revenue
$164,903
$202,125
$207,638
$194,430
Gross Profit
162,020
199,580
203,042
190,997
EBITDA
-44,117
10,392
15,720
32,161
EBIT
-44,715
9,910
15,243
31,692
Net Income
-31,202
24,288
19,668
35,149
Net Change In Cash
164,903
202,125
207,638
194,430
Free Cash Flow
-16,973
38,398
54,481
43,882
Cash
108,738
120,495
125,138
102,745
Basic Shares
104,435
119,855
119,439
120,485

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$761,407
$675,040
$482,375
$401,858
Gross Profit
748,430
664,158
475,894
396,473
EBITDA
68,352
162,829
125,599
115,603
EBIT
66,462
161,493
124,557
112,634
Net Income
99,652
139,733
106,140
101,418
Net Change In Cash
761,407
675,040
482,375
401,858
Free Cash Flow
141,785
195,895
126,900
119,910
Cash
120,495
127,665
135,551
66,329
Basic Shares
119,987
113,480
111,742
115,966

Earnings Calls

QuarterEPS
2026-03-31
-$0.30
2025-12-31
$0.20
2025-09-30
$0.16
2025-06-30
$0.29